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LIVER TRANSPLANTATION 
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and Thomas E. Starzl, M.D., Ph.D. 
Orthotopic liver transplantation has emerged as a 
universal treatment of end-stage liver disease for sev-
eral reasons. We describe this complex undertaking 
starting with the better understood technical consid-
erations, proceeding to the less well understood im-
munologic considerations. and concluding with descrip-
tions of some unresolved issues. We also discuss how 
liver transplantation applies to the treatment of specific 
hepatic diseases and how it has influenced the strategy 
of therapy for those disorders. The issue of auxiliary 
transplantation is discussed as well as transplantation 
of organ combinations,- including multivisceral grafts. 
Developmental procedures that are as yet of unknown 
value are referred to. The literature of this field has 
been so thoroughly catalogued in reviews and other 
books that detailed annotation is unnecessary here. 
Selected references are provided at the end of the 
chapter. with brief annotations. 
The surgical and anesthetic components of the trans-
plantation team play a more central role with liver 
transplantation than with transplantation of any other 
organ. This is not only caused by the difficulty and 
complexity of the operative and perioperative treat-
ment, but also by the high intensity of surgical care 
required for a long time afterward. From the time this 
procedure was introduced 27 years ago until the early 
1980s, liver transplantation was a surgical decathlon, 
with standards only a few surgeons in the world could 
fulfill. It required a combination of skill, strength, and 
speed throughout a race against the clock. 
Although these qualities are still required in some 
cases, the intensity of effort by any single person has 
been reduced by several factors. Responsibilities can 
now be shared. for these procedures are usually done 
in medical centers with teams. The liver allograft is 
frequently shipped in by other teams. Intensive care, 
infectious disease, and other medical specialists meld 
with the anesthesiologists and surgeons imperceptibly, 
as the patient moves from the operating room, through 
the intensive care unit, and onto the wards. 
The transplantation procedure can be divided into 
two parts: the donor operation and the recipient pro-
cedure. 
DONOR OPERATION 
Size Factors 
The donor team must provide moment-to-moment 
information to the recipient surgeons. A liver graft, in 
order to be implanted, has to be similar in size to the 
diseased liver being removed. Thus, optimally, a fairly 
close age match, but especially an organ size match, 
of the donor and recipient would be desirable if the 
whole organ is to be used. Deviations from this rule 
are permissible; such cases usually involve placing 
smaller organs into larger recipients. 
The shortage of pediatric donors and the great 
variability in the needed size led to the utilization of 
reduced-size livers. Liver fragments from donors three 
to four times larger (or even greater) than the recipient 
can be made to fit, if the appropriate size reduction 
procedure is selected. These operations are, in fact, 
formal hepatectomies, performed in the bloodless field 
of the back table. The ones most commonly used are 
a right lobectomy, right trisegmentectomy, and left 
lateral segmentectomy. The resected portion usually is 
discarded. Transplantation of liver fragments is thOUght 
to be associated with a lower incidence of hepatic 
artery thrombosis, because of the larger size of the 
donor artery. The main disadvantage involves compli-
cations from the raw surface, of which hemorrhage, 
biliary fistula, and infections are the most common. 
Graft Assessment 
The American and European experience both show 
that the use of perfect donors with hemodynamic 
stability and normal blood biochemistry values does 
not ensure a great advantage in graft and patient 
survival. Insistence on these ideal donor conditions 
would lead to a waste of an already scarce resource. 
The judgment of whether a graft is transplantable is a 
complex clinical one. The single most important item 
for a final decision is the evaluation of the liver by the 
donor's surgeon. A needle biopsy and pathologic ex-
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FIGURE 41-1. Principle of in situ cooling used for multiple organ 
procurement. With limited preliminary dissection of the aorta and 
the great splanchnic veins, cold solutions can be used to chill organs 
in situ. In this case, the kidneys and liver were removed. Note the 
aortic crossclamp above the celiac axis. Portal perfusion was per· 
formed through a splenic vein cannula. 
amination might help in the case of doubt, by ruling 
out some suspected or unsuspected preexisting disease. 
Harvesting Technique 
Liver allografts are harvested as part of a multiple 
organ procurement, which usually involves renal and 
thoracic teams working in harmony. An inadequate 
performance by one participating group can ruin the 
grafts for all. Skillful liver procurement requires com-
plete knowledge of the anatomy of the hepatic hilar 
structures and its normal variations. In the usual case 
in which the donor's condition is stable, a preliminary 
dissection of all the organs to be removed can be 
performed, and at this time the anatomy is defined. 
When this is completed, the organs are core cooled in 
situ by the rapid infusion of a chilled solution into the 
aorta. For the liver, additional perfusion is provided 
through a separate cannula inserted through the splenic 
vein or other major side branch of the portal vein. 
Venous congestion must be prevented by venting the 
vena cava (Fig. 41-1). 
If the donor is unstable, cooling through the aorta 
can be performed urgently (Fig. 41-2) and the organs 
removed rapidly. In addition to the other organs re-
moved, the iliac vessels and, in small children, the 
carotid arteries of the donor are procured to serve as 
vascular grafts, if needed in the recipient. 
Liver Preservation 
Special solutions to prolong the duration of refrigera-
tion have been used since 1976. The best one currently 
was developed at the University of Wisconsin (UW) 
by Belzer and his associates. This solution provides 
safe preservation of the liver for at least 12 to 16 hours, 
compared with 6 to 8 hours with other solutions. The 
ingredients of the UW solution include lactobionate, 
raffinose, starch, allopurinol, adenosine, and glutathi-
one. Beyond the important benefit of hypothermia 
provided by any cold infusate, these ingredients are 
thought to act by controlling the oncotic ambience of 
the cells, by membrane stabilization, and by enrich-
ment or preservation of the A TP-dependent energy 
state of not only the hepatocytes but also the lining 
cells of the microvasculature. Although the exact role 
of the individual ingredients may be debatable, at-
FIGURE 41-2. If there is no time to insert a splanchnic venous 
catheter for infusion, the rapid infusion of cold fluid into the aorta 
alone will promptly chill the liver because the superior mesenteric 
venous blood contributes to the hepatic cooling. All that is necessary 
is to insert the catheter into the distal aorta and to crossclamp the 
aorta at the diaphragm. OB, gallbladder; SMV, superior mesenteric 
vein; SV, splenic vein; ha, hepatic artery; ca, carotid artery; sa, 
splenic artery; LRA, [left renal artery]; sma, superior mesenteric 
artery; ima, inferior mesenteric artery; RRA, [right renal artery). 
(From Starzl TE. Iwatsuki S, Shaw BW Jr, et al.: Transplant Proc 
17:250--258, 1985.) 
tempts to modify the original UW formula by removal 
of some of the constituents have reduced its effective-
ness. 
The UW solution has had a revolutionary effect on 
liver transplantation: 
1. It has allowed country-wide and sometimes global 
sharing of liver grafts. 
2. It has permitted the procedure to be performed 
semielectively rather than urgently. 
3. It has removed the tight time constraints that 
previously forced the surgeon to proceed with 
implantation of the graft even when the surgical 
field was suboptimally prepared. 
4. It has facilitated the use of reduced-size organs 
by permitting back table procedures. 
These advantages of the UW solution should not be 
construed as an invitation to a leisurely approach to 
liver transplantation. The margin of safety is rapidly 
decreased after 16 to 18 hours of preservation, with a 
nonlinear rise thereafter in primary graft nonfunction. 
Vascular Grafts 
Contrary to the experience with preserved vascular 
allografts, fresh vessels from the same donor provide 
effective and durable vascular conduits when they are 
needed. These free grafts can be preserved in a tissue 
culture medium and refrigerated for 1 or 2 days. It is 
best to utilize vascular grafts from donors of the same 
blood type as that of the recipient or, failing this, from 
donors with a compatible blood group. In the absence 
of cadaver vascular grafts, arterial grafts can be pro-
vided from the internal iliac artery of the recipient or 
the saphenous vein. 
RECIPIENT PROCEDURE 
The recipient procedure consists of four stages: (1) 
recipient hepatectomy, (2) anhepatic phase, (3) im-
plantation, and (4) hemostasis. 
Recipient Hepatectomy 
The classic approach is through a bilateral subcostal 
incision with an upper midline extension. In pediatric 
cases, preoccupation by the surgeon with a rigid and 
an unvarying series of technical steps can be an invi-
tation to disaster, because· the normal anatomy is 
frequently distorted by previous Kasai's operations or 
other procedures. The previous surgery usually has 
been performed through a subcostal incision, and the 
sites of earlier dissection have involved the liver hilum 
and the subhepatic space. It is preferable to enter the 
abdomen through an unviolated area. This entry usu-
ally can be made by incorporating the old scar in a 
larger incision that includes unscarred tissue. 
The hilum is exposed first, if this is simple, and the 
hepatic artery and common bile duct are dissected, 
ligated, and transected (Fig. 41-3). Particular care is 
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FIGURE 41-3. Recipient operation. The hilar structures are dis-
sected. ligated, and divided. The portal vein is cannulated for the 
venovenous bypass. (From Tzakis A. Todo S. Starzl TE: Ann Surg 
210:649-652,1989.) 
exercised to preserve these structures, because they 
are needed later for the anastomosis to the companion 
structures of the new graft. 
If large enough, the patient is placed on venovenous 
bypass. With the native liver devascularized, the liga-
ments are severed, and mobilization is completed (Figs. 
41-3 and 41-4). Control of the infrahepatic and supra-
hepatic vena cava is obtained, and the liver is removed 
after cross-clamping these large vessels. 
Variations of the hepatectomy are too numerous to 
describe here. In principle, control of the hilum and 
the vena cava has to be obtained without damage to 
the transverse colon and duodenum, which are usually 
adherent to the undersurface of the liver from a 
previous operation. A useful approach to the hilum is 
through the lesser sac, whereby the left lateral segment 
is mobilized and the left portion of the gastrohepatic 
ligament is incised. The hilar structures can then be 
identified. as the index finger can be inserted behind 
them from the left side. In uncomplicated cases, the 
approach to the hilum is less difficult from the right 
side. 
The hepatic artery and portal vein are ligated as 
superiorly as possible. When left from a Kasai's oper-
ation, the previously made Roux-en-Y loop is identified 
and ligated as superiorly as possible. At this point, the 
exact location of the colon and duodenum is better 
known, and they are separated from the liver. After 
devascularizing the liver, the inferior vena cava is 
controlled and clamped, and the liver is removed. The 
right adrenal vein, which enters the retrohepatic vena 
cava, must be ligated if the vena cava segment is 
removed. 
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The hilum of the liver is at times unapproachable 
from the inferior surface of the liver. In these cases, 
the suprahepatic cava can be dissected out first and 
clamped. The liver side of the cava is occluded by 
inserting the index finger (Fig. 41-5) or by oversewing. 
This maneuver allows the liver to be shelled out from 
above. As the liver comes down, it is attached to a 
stalk consisting of. the retrohepatic vena cava and the 
hilar structures. These are increasingly accessible as 
the liver is mobilized from the wound and can be 
individually controlled and transected, as the liver is 
removed. 
Anhepatic Phase 
The anhepatic phase marks the time between the 
clamping of the portal vein and inferior vena cava and 
the revascularization of the new graft. During this 
time, systemic and portal venous beds are obstructed, 
unless a venovenous bypass is used. The consequent 
insult of venous hypertension is better tolerated by 
children than by adults, but even in children this is a 
time of urgency. It may be necessary to sew in the new 
liver in the presence of cardiovascular instability, which 
can be life-threatening. 
VENOVENOUS BYPASS. The venovenous bypass was 
designed to avoid these dangerous changes. It consists 
of an extracorporeal circulation, whereby blood is 
pumped from the inferior vena cava and portal vein to 
the superior vena cava. The portal vein is cannulated 
directly through its transected end, whereas the inferior 
and superior venae cavae are cannulated through the 
saphenous and axillary veins (Fig. 41-4). Heparin-
bonded shunts or chest tubes are employed as venous 
cannulas. How is maintained with a Biomedicus pump 
000 00 
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FIGURE 41-4. Pump-driven ve-
novenous bypass, which allows de-
compression of the splanchnic and 
systemic venous beds without the 
need for heparinization. 
(Biomedicus, Inc., Minneapolis, MN). With appropri-
ate size selections of the tubing and pump head, a flow 
of 500 mllmin or more provides protection from clot-
ting. Clotting abnormalities due to liver disease act as 
natural anticoagulants. With this technique, the portal 
venous return is interrupted only for the time required 
for construction of the portal anastomosis, during 
which time vena caval decompression is continued. 
Bypass usually can be done with children larger than 
15 kg body weight, but it is an increasingly difficult 
and unreliable technique with children smaller than 
this. 
PIGGYBACK LIVER TRANSPLANTATION. This tech-
nique is particularly helpful when venovenous bypass 
is not possible and allows the recipient vena cava to 
remain intact throughout the procedure. The liver is 
stripped off the vena cava (Fig. 41-6), ligating and 
dividing hepatic vein tributaries. An ostium is created 
to receive and transmit the venous outflow from the 
graft, by joining the mouths of the left and middle, 
the middle and right, or all the upper hepatic veins. 
The suprahepatic vena cava of the graft is anastomosed 
to this opening (Fig. 41-7). The stripping of the liver 
from the vena cava can be tedious and dangerous. 
Should this be the case, the segment of retrohepatic 
vena cava should be removed, and a conventional 
procedure is then performed with replacement of the 
vena caval segment (Fig. 41-8). 
Maintenance of cardiovascular stability of the recip-
ient with the venovenous bypass or with piggyback 
techniques has allowed liver transplantation to be 
performed in the most technically demanding cases. 
These techniques also allow hemostasis and prepara-
tion of the recipient field under more satisfactory 
circumstances. 
FIGURE 41-5. Removal of the liver from above downward, pre-
venting hemorrhage with a finger or fingers thrust down the lumen 
of the transected suprahepatic vena cava. The maneuver is indicated 
if it is difficult or impossible to safely encircle the inferior vena cava 
below the liver. This technique is specific for certain cases of biliary 
atresia with extensive subhepatic scarring in which the small size of 
these livers makes it possible to completely occlude the vena cava 
with a single finger. 
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FIGURE 41-6. Steps in preparation of the recipient vena cava for 
the piggyback operation. All the small hepatic veins entering the 
retrohepatic vena cava are ligated and divided. and the large 
principal tributaries (right, middle, and left hepatic veins) are 
dissected free. IVe, inferior vena cava. (From Tzakis A, Todo S, 
Starzl TE: Ann Surg 210:649-652. 1989. Used by permission.) 
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Implantation 
In the usual case, the suprahepatic vena caval anasto-
mosis is performed first (Fig. 41-8). The infrahepatic 
vena caval anastomosis is then performed while the 
liver is flushed with cold lactated Ringer's solution to 
remove air and debris and the high potassium load 
that is in most preservation fluids. When the liver is 
placed piggyback, a lower caval anastomosis is not 
needed, and the stump is either ligated (Fig. 41-9) or 
oversewn. 
The third anastomosis involves the portal vein (Figs. 
41-8 and 41-9). When it is completed, the liver is 
perfused. The portal vein anastomosis is end to end. 
If the recipient portal vein is clotted or not usable, 
dissection of the recipient portal vein to the confluence 
FIGURE 41-7. Cuffs are fashioned for the outftow anastomosis. 
(From Tzakis A, Todo S, Starzl TE: Ann Surg 210:649-652, 1989.) 
of the superior mesenteric vein and splenic vein may 
be needed. Reconstruction can be performed from this 
junction directly to the donor portal vein or indirectly, 
via an interposition venous graft. An alternative and 
usually simpler solution is a venous jump graft that is 
anastomosed to the side of the recipient superior 
mesenteric vein and led to the donor portal vein 
through an opening in the transverse mesocolon and 
behind the antrum of the stomach (Fig. 41-10). 
The arterial anastomosis is performed as the final 
step of revascularization, although the surgeon may 
elect to perform it before the portal reconstruction. In 
that case, the liver can be perfused with arterial blood 
first. Alternatively, revascularization can be deferred 
until all vessels have been reconstructed. 
Many permutations of the arterial reconstruction 
FIGURE 41-8. Orthotopic liver transplantation (liver replacement). 
Biliary tract reconstruction usually is with choledochojejunostomy 
(to a Roux-en-Y limb) or with choledochocholedochostomy (insert), 
which is stented with a T tube. 
FIGURE 41-9. Transplantation of the liver piggyback 
onto the recipient inferior vena cava (rvC). which is 
preserved through its length. Note that the suprahe· 
patic vena cava of the homograft is anastomosed to 
the anterior wall of the recipient vena cava. The 
retrohepatic vena cava of the homograft is sutured or 
ligated. leaving a blind sac into which numerous hepatic 
veins empty. Ao. aorta. (From Tzakis A. Todo S, 
Stam TE: Ann Surg 210:649-652. 1989. Used by 
permission. ) 
have been described, because donor and recIpIent 
anomalies are so common. Significant donor variations, 
which are seen in about one third of the cases, include 
anomalous branches to the hepatic graft from the aorta 
directly or from the left gastric or superior mesenteric 
artery. Examples of reconstructions of the donor ar-
terial abnormalities are shown in Figures 41-11 and 
41-12. These usually are performed on the back table 
so that only a single arterial anastomosis to a recipient 
vessel or vascular graft is necessary, after the liver is 
brought into the operative field. 
RECIPIENT VARIATIONS. The recipient arterial anat-
omy has the same anomalies. In addition, arterial 
disease or surgical damage may render the recipient 
vessel unusable for arterialization. This problem can 
be overcome with vascular grafts, which usually are 
"jumped" from the recipient infrarenal aorta (Fig. 41-
13) and, occasionally, from the recipient suprarenal 
aorta or one of the iliac arteries. 
BILIARY RECONSTRUcnON. If possible, an end-to-
end choledochocholedochostomy with a T tube is per-
formed (Fig. 41-8). If this procedure is not feasible, 
choledochojejunostomy with a defunctionalized Roux-
en-Y limb is the alternative (Fig. 41-8). In children, 
the Roux-en-Y technique is required in more than 90% 
of cases. 
TECHNICAL COMPLICATIONS 
Liver transplantation is an unforgiving procedure. Peri-
operative bleeding is a constant threat, which may be 
compounded by existing coagulopathy in graft dys-
function. Any major technical imperfection is almost 
certain to result in· a complication or frequently a 
cascade of complications. The most serious complica-
tions are graft devascularization with gangrene and 
biliary fistulas or obstructions. 
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The clinical presentation of most technical compli-
cations can mimic rejection. If a technical complication 
is misdiagnosed as rejection, an unjustified increase in 
immunosuppression can amplify the intrinsic risk of 
the original misadventure. Consequently, rejection 
Native sup. 
mesenteric 
FIGURE 41-10. A vein graft for portal vein reconstruction when 
thrombosis of the recipient portal. splenic, or superior mesenteric 
vein precludes a standard operation. Note that the vein graft is 
jumped from the distal superior mesenteric vein through the trans-
verse mesocolon over the pancreas and behind the pylorus. 
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FIGURE 41-11. A. The hepatic arterial supply in this case comes from both the celiac axis and superior mesenteric artery of the donor 
liver. 
B. Reconstruction by anastomosis of the graft right hepatic artery rising from the superior mesenteric artery to the splenic artery. 
C. d. common duct; Lga. left gastric artery; Lha. left hepatic artery; Mha, middle hepatic artery; Rha. right hepatic artery; Sa. splenic 
artery; Sma. superior mesenteric artery. 
should be confirmed only after the anatomic integrity 
of the graft has been established by the appropriate 
diagnostic 'Steps. 
Hepatic Artery Thrombosis 
Hepatic artery thrombosis is the most common tech-
nical complication leading to graft failure or to death. 
Nontechnical factors causing thrombosis include exces-
Middle 
Celiac A~il 
/' 
sive intraoperative and perioperative clotting factors 
and platelet infusions. Protein C, which is a natural 
anticoagulant produced by the liver, may be deficient 
after liver transplantation. 
Most hepatic artery thromboses occur within hours 
or days after liver transplantation. Color Doppler 
ultrasound is reliable for detecting the event, but it is 
less reliable in smaller children. Also, in cases of 
rejection. the hepatic artery is difficult to detect by the 
Ri9ht 
Hepatic' 
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FIGURE 41,..U. Alternative method of vascular reconstruction used for the anomaly shown in Figure 41-11. The homograft celiac axis is 
anastomosed to the homograft superior mesenteric artery. These versions differ only in that the opposite ends of the superior mesenteric 
artery are used for the anastomosis to the recipient vessels. 
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FIGURE 41-13. An antepancreatic route for a vascular graft placed 
onto the infrarenal abdominal aorta. The graft is brought either to 
the right or left of the middle colic vessels. anterior to the pancreas. 
and beneath the pylorus. (From Tzakis AG. Todo S. Starzl TE: 
Transplant lnt 2: 121. 1989. Used by permission.) 
Doppler technique. because the arterial flow is damp-
ened. The diagnosis can be made with certainty only 
with arteriography. The incidence of hepatic artery 
thrombosis in pediatric liver transplantation has been 
reported as 5 to 30% and is roughly inversely propor-
tional to recipient size. 
In about a third of cases with hepatic artery throm-
bosis, the patient is asymptomatic. Symptomatic 
thrombosis may occur in three forms, which can have 
some overlap: fulminant hepatic failure with liver gan-
grene, requiring immediate retransplantation; biliary 
complications, such as delayed bile leak or biliary 
strictures; and episodes of chronic bacteremia, with or 
without visible intrahepatic abscesses. 
Although medical factors can be contributory, the 
role of seemingly minor technical errors in the etiology 
of hepatic artery thrombosis cannot be overempha-
sized. Perioperative administration of heparin and 
platelet aggregation inhibitors may be useful. In infants 
and smaller children, we administer these routinely for 
the duration of hospitalization. 
Biliary Complications 
Early and late biliary complications were once the 
greatest threat to liver transplantation. This threat has 
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been reduced by improved techniques, including avoid-
ance of gallbladder conduit and cholecystenterostomy 
techniques. Now, only duct-to-duct or duct-to-Roux-
en-Y limb reconstruction is used. Another ameliorating 
factor has been improved organ preservation. Never-
theless, biliary tract complications still occur at a rate 
of 10 to 15% and directly result in 2 to 10% of the 
global mortality rate in various reported series. In 
present-day practice, hepatic artery thrombosis is sus-
pected whenever there is a biliary complication, be-
cause the principal blood supply of the graft bile duct 
is arterial. 
Primary Graft Dysfunction 
Approximately 10 to 15% of liver allografts have to be 
replaced within 2 months after transplantation, because 
they do not function adequately. In the extreme case 
of allograft nonfunction, survival for more than a few 
hours is not possible unless a second graft can be done. 
The most common reason for such a disaster is an 
imperfect donor or recipient operation. but there are 
numerous other reasons that may blight a seemingly 
perfect technical performance. 
Humoral rejection should be suspected if the trans-
plantation was with a positive cytotoxic crossmatch or 
with an ABO incompatible blood donor (discussed 
later). Endotoxemia, which can activate many of the 
same mediators involved in humoral immune reactions, 
has been suspected. Many other incompletely under-
stood issues, including therapeutic errors, can contrib-
ute to primary graft dysfunction or nonfunction. 
IMMUNOLOGIC CONSIDERATIONS 
A perfect operation is only the beginning of a lifelong 
commitment to maintain the integrity of the graft 
against natural forces designed to destroy it by rejec-
tion, infection with viruses or other pathogens, or 
blood supply disruption or biliary drainage. In the 
long-range perspective, rejection still is the most com-
mon cause of graft loss. 
It is known from animal observations that the liver, 
in relation to other organs, is naturally protected from 
humoral and cellular rejection. As a practical consid-
eration, this advantage must be considered academic, 
as illustrated by the fact that consistently successful 
liver transplantation was not possible in humans until 
sophisticated and potent immunosuppression became 
available with the advent of cyclosporin A in 1980. For 
practical purposes, three forms of rejection have been 
defined: (1) humoral or hyperacute, (2) acute or cel-
lular, and (3) chronic. 
Humoral Rejection 
The term humoral refers to the rejection by preformed 
antibodies. The resistance of the liver to preformed 
antigraft antibodies is exemplified by the fact that liver 
transplantation often can be carried out successfully 
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with ABO incompatibility. However, the penalty for 
violating ABO compatibility rules is an increased rate 
of graft loss. A blood group-incompatible graft should 
be accepted only if in the most extreme urgency. The 
offending antigraft antibodies are isoagglutinins of both 
IgG and IgM classes, which can cause clots that plug 
the liver microvasculature. 
If livers are exposed to the cytotoxic antibodies that 
connote presensitization to histocompatibility and 
other antigens, the same disruption of the graft micro-
vasculature can occur, although less commonly and 
more slowly than in heart or kidney grafts. Rats and 
monkeys presensitized with repeated donor skin grafts 
have been shown to reject livers within hours after 
transplantation. Pathologic findings include immuno-
globulin deposits, arteritis, and ischemic necrosis of 
the graft. Similar observations have been made in 
humans. although this kind of fulminant rejection is 
not necessarily associated with demonstrable pre-
formed antidonor cytotoxic antibodies. Nevertheless, 
a positive cytotoxic crossmatch degrades the prognosis. 
Although not invulnerable to humoral rejection, the 
liver's relative resistance to this process is not under-
stood. The liver graft may neutralize existing antibodies 
by Kupffer's cell action, or by secretion of soluble class 
I major histocompatability complex (MHC) antigens, 
which neutralize or alter the antibodies. 
The price of carrying out liver transplantation with 
a positive lymphocytotoxic crossmatch is an early graft 
failure rate that may be as high as 30%. In spite of 
this, we do not allow a positive crossmatch to deter 
transplantation if there is overriding need. Patients 
with wide-ranging cytotoxic antibodies usually react 
against all donors, and if their need for a new liver is 
great, they will die while waiting for a negative cross-
match donor. 
Acute or Cellular Rejection 
Acute or cellular rejection is characterized by the 
invasion of mononuclear cells, which are concentrated 
heavily in the portal triads. The intrahepatic bile ducts 
are the most specific targets of destruction, but the 
arteries and portal veins are also attacked. Conse-
quently, a decline in total hepatic blood flow is char-
acteristic during rejection. The central veins also can 
be invaded, leading to obliterative endophlebitis and 
subsequent outflow block, as in the Budd-Chiari syn-
drome. Graft edema, intrahepatic cholestasis, and var-
ious degrees of parenchymal damage are other findings. 
Successful treatment can result in complete resolu-
tion of these findings. Failure to control the process 
results in early destruction of the graft or, if incom-
pletely treated, in chronic rejection. 
Chronic Rejection 
Chronic rejection is characterized by occlusive arterial 
disease, disappearance of the intrahepatic bile ducts 
(disappearing bile duct syndrome), and varying degrees 
of fibrosis, A sparse but strategically located cellular 
infiltrate in the portal tracts is characteristic. Antibod-
ies also may playa role. Chronic rejection is most 
frequ.ently ~anife~ted by obst~c~i~e jaundice pro-
gressmg to hver fadure after an Imtlal period of rela-
tively good preservation of synthetic and other paren-
chymal function. 
The clinical presentation occurs hours or days after 
transplantation in the case of humoral rejection. Acute 
rejection can occur at any time but usually is days or 
weeks after transplantation. The pathologic findings of 
chronic rejection are usually evident in biopsy samples 
obtained months or years after transplantation but have 
been recorded as soon as 3 or 4 weeks. Efforts at such 
clear categorization may be fruitless, because acute 
rejection can follow a sublethal humoral rejection, and 
chronic rejection usually is the consequence of a par-
tially treated or neglected acute rejection. 
Graft vs. Host Disease 
The liver graft is not only the target of immune attacks 
but also is capable of mounting immunologic reactions 
against the host, resulting in graft vs. host disease 
(GVHO). The incidence of GVHO is not known 
precisely, because it can be mild and therefore difficult 
to recognize. A special kind of GVHO is that seen 
after transplantation of the liver from a donor of a 
compatible but not identical major blood group (0 to 
A, for example). Under these circumstances, hemolysis 
can be caused by isoagglutinins produced by lymphoid 
elements in the graft or migrating from it, which bind 
to and destroy recipient red blood cells. 
IMMUNOSUPPRESSION 
This discussion is limited to drugs that are currently 
utilized for clinical liver transplantation. 
Glucocorticoids 
Glucocorticoids were the first drugs in liver transplan-
tation to reduce the body's immune defenses. They are 
given in combination with other immunosuppressants 
as maintenance treatment for prevention of rejection. 
They may be administered in much higher doses for 
single-dose bolus or short-course therapy. Prednisone 
and methylprednisolone are the principal agents. 
The steroids are the most dose-maneuverable of aU 
the immunosuppressive agents. Their action on the 
immune system is diffuse. Long-term high-dose steroid 
therapy will stunt growth in children and produce 
intolerable cosmetic deformation, including moon fa-
cies, buffalo hump, abdominal striae, and bone abnor-
malities. Steroids also create a fertile soil for oppor-
tunistic infections, Steroid therapy has thus been called 
the curse of survival. 
Azathioprine 
This purine antimetabolite, a derivative of 6-mercap-
topurine, is useful for the prevention of rejection but 
not for its reversal. It was the first commonly admin-
istered chemotherapeutic agent. beginning in 1962. but 
now is employed as an adjuvant agent in drug cocktails 
based on cyclosporine, or FK 506, and prednisone. 
Azathioprine is used as a means of reducing the 
necessary doses of cyclosporine and the threat of 
cyclosporine nephrotoxicity. It is myelotoxic and must 
be monitored with frequent white blood cell count 
determinations. Azathioprine diffusely weakens im-
mune defenses, in contrast to the more specific action 
of cyclosporine and FK 506. 
Antilymphocyte Globulin 
Antilymphocyte globulins (ALGs) are polyclonal or 
monoclonal antilymphoid antibodies designed to elim-
inate lymphocytes from the circulation and lymphoid 
depots of the recipient. They are given for treatment 
of rejection or from the time of operation for prophy-
laxis. The first ALGs were raised by immunizing rab-
bits, horses, or goats with lymphoid tissue (splenic, 
lymph node. thymic. or thoracic duct lymphocytes) 
and by purifying the IgG fraction in which the desired 
antibodies were found. Using cultured B lymphocytes 
as the immunizing antigen produced a more predictable 
product. However. all the ALGs represent a complex 
(polyclonal) response of the immune apparatus of the 
immunized animal. and thus. they have as their target 
a diffuse collection of recipient lymphoid and usually 
other cells. 
With the hybridoma technique pioneered by Kohler 
and Milstein of England. a more sophisticated ALG. 
called OKT3, was developed which is produced by a 
single (monoclonal) immortalized cell. The target of 
OKT3 is the mature T lymphocyte. Since the clinical 
introduction of OKT3 by Cosimi of Boston, increas-
ingly specific monoclonal ALGs have been produced 
by different hybridomas. These newer products can 
target lymphocyte sub populations of T lymphocytes or 
sites of cytokine binding (interleukin-2 binding sites, 
for example). Their clinical use is still under investi-
gation. 
The efficacy of the established preparations of ALGs 
is beyond doubt but has been attended by a high rate 
of infection, particularly by viruses such as cytomega-
lovirus (CMV). In addition, the animal origin of the 
immunoglobulin (even the monoclonal preparations, 
raised with mouse hybridomas) led to rapid sensitiza-
tion; immune elimination of the foreign proteins with 
LIVER TRANSPLANTATION 515 
progressive loss of biologic potency; and potential for 
foreign protein reactions, such as anaphylaxis and 
serum sickness nephritis. Consequently, ALGs can be 
provided for only a limited time. 
Cyclosporine 
Cyclosporine is produced from a soil fungus Tricho-
derma polysporum. Unlike the immunosuppressive 
drugs that preceded it, cyclosporine is selective. It 
inhibits the activation of T -helper lymphocytes and 
suppresses the synthesis and expression of interleukin-
2, gamma interferon, and other cytokines. The value 
of this specificity is partly lost, because the doses that 
can be administered are limited by nephrotoxicity, 
hypertension, and other side effects. Consequently, 
cyclosporine is combined with nonspecific drugs, such 
as azathioprine, steroids, and ALGs. Nevertheless, 
cyclosporine has had a revolutionary impact on trans-
plantation. 
FK 506 
The drug, produced from Streptomyces tsukubaensis, 
has been in clinical use since early 1989. Although it 
is unrelated chemically to cyclosporine and has a 
different binding site, its immunologic targets are sim-
ilar to those of cyclosporine. It appears to have a better 
therapeutic margin, and although often given with 
steroids, it is potent enough to be given alone (mono-
therapy) in the majority of cases-within 1 to 3 months 
after liver transplantation. A voiding steroid therapy 
thereby is an overriding advantage in pediatric trans-
plantation. In addition, the distressing hirsutism and 
coarsening of facial features often observed with cyclo-
sporine are not observed with FK 506. Although, like 
cyclosporine, it is nephrotoxic, hypertension has not 
been common. 
Complications of immunosuppression are derivative 
from the loss of immunologic defenses and specific to 
the drugs. The most serious generic complications from 
immunosuppression are (1) opportunistic infections 
(viral, bacterial, fungal, and protozoal), (2) lympho-
mas, which usually are B-cell tumors associated with 
Epstein-Barr virus, and (3) high incidence of epithelial 
and other nonlymphoid and hematopoietic malignan-
cies. Complications specific to the individual drugs are 
listed in Table 41-1. 
TABLE 41-1. Toxicity of Immunosuppressive Agents Currently in Use 
Complication Prednisone Azathioprine 
Myelotoxicity + 
Neurotoxicity + 
NephrotOxicity 
Diabetes + 
Hirsutism + 
Gum hyperplasia 
Hypenension + 
Wound healing + 
Facial brutalization + 
Obesity + 
+ = pOIential complication; ? = potential for this reaction is unknown. 
ALG 
? 
? 
Cyclosporine 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
FK506 
+ 
+ 
+ 
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SPECIFIC PEDIATRIC DISEASES 
Biliary Atresia 
Biliary atresia is defined as the congenital absence or 
inadequacy of canalization of the extrahepatic biliary 
system. Its incidence is one in 8000 to 15,000 live 
births, with approximately 400 new cases reported in 
the United States per year. Portoenterostomy (Kasai's 
procedure), which was introduced 2 decades ago to 
surgically drain the intrahepatic ducts, was the first 
procedure to provide any hope for victims of this 
wretched disease. However, even with relief of jaun-
dice following Kasai's operation, biliary cirrhosis de-
velops with variable speed in most patients. 
Grossly evident bile drainage can be seen at the time 
of Kasai's procedure in almost 90% of infants who 
have undergone operation before the age of 2 months. 
The prognosis is considered better if there is a signifi-
cant duct or large ductules in the porta hepatis or if . 
there is bile bilirubin that can be drained at greater 
than 6.8 mg/lOO ml. 
Kasai's procedure was like a beacon of light when it 
was introduced. because there was no alternative ther-
apy. Under these circumstances, success understanda-
bly was judged by bile production, elimination or 
improvement of jaundice, prolongation of life beyond 
a few months. and signs of physical or mental growth. 
All too often, the procedure merely prolonged a mor-
bid life in a child deprived of normal growth and 
activities, whether jaundiced or not. Few patients have 
grown to normal teenage or adult life. Even those with 
successful Kasai's operations usually have died after a 
number of years or eventually have required transplan-
tation. 
Prior portoenterostomy can complicate the liver 
transplantation. In most cases, technical problems 
caused by previous operations are manageable by 
skilled teams. In a significant number of patients the 
combination of portal hypertension and dense surgical 
scarring makes the liver transplantation complicated 
and among the most dangerous procedures in pediatric 
surgery. Consequently, the role of Kasai's operation is 
being evaluated critically. 
It may be that an attempt to drain the biliary system 
with Kasai's operation by an experienced surgeon can 
be justified, if the liver still appears relatively undam-
aged and other conditions are propitious. However, 
when the liver is damaged or cirrhotic, a portoenter-
ostomy is more apt to be harmful than helpful. The 
argument has lost force that time can be bought with 
Kasai's operation to allow growth to a more reasonable 
size, not only because this is so often not achieved, 
but also because of greater success after transplantation 
in tiny recipients. Liver transplantation is the only 
treatment with which the disease is definitively recti-
fied, with subsequent normal liver function, normal 
development, and complete rehabilitation. The attrac-
tion of transplantation as the primary therapy is in-
creasingly difficult to resist. 
Arteriohepatic Dysplasia 
Arteriohepatic dysplasia (Alagille's syndrome) is a 
genetic disorder transmitted via an autosomal domi-
nant gene with variable expression and penetrance. It 
is characterized by the combination of a broad fore-
head, pointed chin, ve~ebral de~ectsI pul~onary artery 
stenOSIS, and cholestasls. Kasal s operatIOn is not in-
dicated. Characteristically, the liver disease has a fairly 
slow progress compared with biliary atresia. Trans-
plantation is usually needed eventually. Cardiac angi-
ography is often necessary for the evaluation. 
Inborn Errors of Metabolism 
Patients with liver-based inborn errors of metabolism 
can be treated by providing a phenotypically normal 
liver. Several products of hepatic synthesis perma-
nently retain the original metabolic specificity of the 
donor after transplantation. These observations made 
it virtually certain that liver transplantation would 
become a decisive way to treat the inborn errors of 
metabolism that resulted partly or completely from 
deficiencies of specific liver enzymes or from abnormal 
products of hepatic synthesis. 1 
This expectation has been fulfilled in many patients, 
some of whom have been followed for as long as 19 
years after transplantation (Table 41-2). With other 
disorders in which the pathogenesis was not well under-
stood, the transplantation itself became a powerful 
research tool by showing the extent of correction with 
a new liver and by elucidating the mechanisms by 
which correction was accomplished (see Table 41-2). 
In the majority of recipients, the inborn error had 
itself been responsible for damage to the liver, and the 
conventional indications of liver failure or the devel-
opment of malignant tumors prompted the liver re-
placement. However, an increasing number of trans-
plantations have been carried out solely for the purpose 
of correcting the inborn error. In many of these pa-
tients (see Table 41-2), the excised liver has been 
anatomically normal. 
Hepatitis Virus B 
Although hepatitis virus B (HVB) can cause fulminant 
or chronic liver failure necessitating liver transplanta-
tion in children, the principal experience has been in 
adults. Such efforts have been plagued by disease 
recurrence in the new liver, often necessitating retrans-
plantation. No reliable means exist to avoid recurrence. 
When serial retransplantations have been attempted, 
the progression of the disease in the new liver has been 
faster each time. Active and passive immunization and 
interferon-a therapy have not altered the outcome in 
most cases. However, about 20% of our patients have 
cleared the HVB surface antigen (HB.Ag) after trans-
plantation. Almost all these successfully treated pa-
tients . were operated on when there was minimal evi-
dence of viral replication (HBeAg negative). 
--------------------------------- ---
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TABLE 41-2. Inborn Errors of Metabolism Treated with Liver Transplantation 
Correction of 
Disease Mechanism of Disease Metabolic Defect Longest Survival Associated Liver Disease 
Alpha,-antitrypsin 
deficiency 
Wilson's disease 
Structural abnormality of the 
protease inhibitor synthesized 
in liver 
Abnormal biliary-copper 
excretion. decreased copper 
binding to ceruloplasm. and 
copper accumulation in tissues: 
autosomal recessive gene 
mapped to chromosome 13 
Yes 14 years' Cirrhosis 
Yes 17.5 years' Cirrhosis 
Tyrosinemia Fumarylacetoacetate hydrolase Nearly complete 8.5 years' Cirrhosis. hepatoma 
Type I glycogen storage 
disease 
deficiency 
GIucose-6-phosphatase deficiency Yes 8 years' Glycogen storage, fibrosis. 
tumors 
Type IV glycogen storage 
disease 
Amylo-l.4-transglucosidase Incompletet 6 years' Cirrhosis 
(branching enzyme) defect 
Cystic fibrosis Unknown; pancellular disease, Not known 6 years' Cirrhosis 
liver often affected 
Nieman-Pick disease Sphingomyelinase deficiency, Not known 2 years (patient died) None 
sphingomyelin storage 
Unknown; neurovisceral No 8 years' Cirrhosis 
lipochrome storage 
Sea-blue histiocyte 
syndrome 
Erythropoietic 
protoporphyria 
Hepatic ferrochelatase deficiency, Incomplete 2.5 years Cirrhosis 
Crigler-Najjar syndrome 
Type I hyperoxaluria 
Urea cycle enzyme 
deficiency 
? overproduction of 
protoporphyrin by 
erythropoietic tissues 
Glucuronyltransferase deficiency 
Peroxisomal alanine: glyoxylate 
aminotransferase deficiency 
Ornithine carbamoyltransferase 
deficiency 
Defective C protein synthesis 
Yes 5 years None 
Yes 8 months None 
Yes 2.5 years' None 
Yes 3.25 years' None C protein deficiency 
Familial 
hypercholesterolemia 
Hemophilia A 
LDL receptor deficiency, (patient Incomplete 63/4 years' None 
died), LDL overproduction 
Factor VIII deficiency Yes 4 years' (patient died Cirrhosis, a complication of 
of AIDS) blood component therapy 
Hemophilia B Factor IX deficiency Yes 6 months Cirrhosis. a complication of 
blood component therapy 
'Patients in University of Colorado-University of Pittsburgh series. Follow-up to January 1989. 
+ Amylopectin deposits found in hean biopsy 4 years after transplantation. 
Modified from Starzl TE. Demetris AI: Liver Transplantation. Year Book Medical Publishers, Chicago, IL, 1990. 
Hepatitis C 
Hepatitis C (non-A and non-B) is the leading viral 
cause of chronic active hepatitis leading to transplan-
tation. The virus can also cause recurrent disease in an 
otherwise successfully transplanted liver allograft. Se-
rologic tests that allow epidemiologic studies have been 
available only for about 1 year. However, these tests 
have helped establish the fact that interferon-a therapy 
can be effective in treating recurrent disease. If recur-
rent hepatitis is suspected, it must be differentiated 
from rejection. This is not always simple, even with 
biopsy studies. 
Primary Hepatic Malignancies 
Unsuspected tumors found during liver transplantation 
for end stage liver disease are called incidental. They 
have a low rate of recurrence. 
Total hepatectomy and liver transplantation may be 
the only means of removing the kind of extensive 
hepatic malignancy that is the primary reason for 
consideration of transplantation. Primary hepatic ma-
lignancies are relatively uncommon in the pediatric 
population and account for less than 5% of the liver 
transplant cases. The pediatric experience at the Uni-
versity of Pittsburgh is summarized in Table 41-3. The 
results were better with hepatoblastomas and incidental 
hepatomas than with large primary hepatomas. The 
patients with hepatoma often died later from metas-
tases. Chemotherapy is thought to have an important 
role in the treatment of hepatoblastoma. The role of 
chemotherapy in the treatment of hepatomas is less 
clear and is under evaluation. 
MULTIVISCERAL TRANSPLANTATION 
Multivisceral transplants that include the liver have 
been used to treat a few patients who have experienced 
the failure of more than one visceral organ system, or 
in an effort to extirpate tumors beyond the field of a 
>:tisrsll 
TABLE 41-3. U.er ThmspIoa ..... for Primory Hep'" M ........... I the U.........,. of PiIII.......1 
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No. of No. of Mean Follow-up No. of Mean Time 
Pathology Pis. Pis. Alive of Survivors Pis. Dead to Death Cause of Death 
Hepatocellular carcinoma 
Tumor size <2 cm' 7 6 6:15 years 1 3 years Postsplenectomy sepsis 
Tumor size >2 cmt 8 2 2:42 years 6 2 years Recurrence in 5 patients+; 
Iymphoproliferative disease 
in 1 patient 
Hepatoblastoma 6 5 19.6 months 2 months Recurrence 
• All tumors in this group were incidental: 5 occurred in tyrosinemia patients. 
tTwo patients in tbis group underwent upper abdominal exenteration and pancreatic islet transplantation and are excluded from the table. 
~Mean time to death from recurrence was 8 months. 
standard total hepatectomy. With full multivisceral 
transplantation, all the intraabdominal organs except 
the spleen make up the allograft. Two children in the 
Pittsburgh experience lived for 36 and 192 days after 
this operation under cyclosporine immunosuppression, 
but both died of lymphoproliferative tumors (B cell 
lymphomas), which involved the liver and intestine. 
Margareiter of Innsbruck. Austria, has had survival of 
81/2 months after this operation in an adult patient who 
eventually died of recurrent carcinoma of the pancreas. 
Our longest surviving patient and Margareiter's patient 
had function of all the organs of their composite grafts. 
The feasibility of multi visceral transplantation is sug-
gested by the lifetime survival in good health of rats 
at a result that is more easily achieved than that with 
transplantation of the intestine alone. 
Less extreme variations of the multivisceral allograft 
have included the so-called cluster transplant in which 
the intestine and stomach are discarded. With this 
operation. the liver, pancreas, and a segment of duo-
denum are utilized to replace the recipient resection 
specimen, which includes the liver, pancreas, spleen, 
stomach. dUodenum, and variable lengths of jejunum 
and colon (Fig. 41-14). The cluster operation was 
designed for extensive tumors involving the liver, pan-
creas, or other upper abdominal organs and has been 
used mainly in adults. However, one of our pediatric 
patients who underwent upper abdominal exenteration 
had whole organ replacement of the liver only but was 
also given pancreatic islets from the same donor (Fig. 
41-15). She has been insulin-free and without tumor 
recurrence (hepatoma) for more than a year. She 
represents the first unequivocally successful case of 
pancreatic islet transplantation. 
Two more children with absent intestines and liver 
failure secondary to massive perinatal enterectomy and 
hyperalimentation have had combined liver and intes-
tinal transplantation (Fig. 41-16) under FK 506 with 
good results 2 and 7 months later. This operation was 
first performed successfully by Drs. David Grant and 
William Wall of London, Ontario. We also are follow-
ing an adult who underwent this procedure, as well as 
another adult who underwent a complete small bowel 
homograft. Four of four patients provided with com-
plete small bowel transplants using FK 506 are living. 
The limited exploitation of the multivisceral proce-
dures, especially those that include the intestine, may 
change. The lymphoid components of these grafts, 
which have been feared as a cause of G VHD, actually 
undergo repopulation with recipient IYOlphoreticular 
cells. Previously, the appearance of recipient cells in 
these grafts was equated with rejection rather than 
construed as desirable. The repopulation without graft 
destruction was not consistently achieved or under-
stood. until the more potent immunosuppression with 
FK 506 became available. 
FIGURE 41-14. Completed cluster implantation after upper abdom-
inal exenteration. 
FIGURE 41-15. Liver and pancreatic islet transplantation after 
upper abdominal exenteration. (From Tzakis AG, Ricordi C. Ale-
jandro R. et al.: Lancet 336:402-405. 1990.) 
DONOR RECIPIENT 
FIGURE 41-16. A, Graft used for combined liver and small intestine transplantation. 
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B, Operative field after hepatectomy. Note that the recipient portal vein has been anastomosed to the vena cava for decompression of the 
viscera left behind. 
C. Completion of the liver-intestinal graft. At this time the previously placed portacaval shunt (see B) can be taken down and the recipient 
portal vein anastomosed to the side of the graft portal or superior mesenteric vein. 
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RESULTS OF PEDIATRIC LIVER 
TRANSPLANTATION 
Effect of Immunosuppression 
The results of conventional liver transplantation can 
be categorized into three successive periods, which are 
defined by the immunosuppressive agents available 
during those periods. These periods have been called 
the (1) azathioprine era, in which azathioprine some-
times replaced with cyclophosphamide and prednisone 
(with or without ALG) were used; (2) cyclosporine 
era, in which cyclosporine and prednisone, with or 
without azathioprine and ALG (most frequently 
OKT3) were used; and (3) FK 506 era, in which FK 
506 and prednisone, with or without ALG (always 
OKT3) were available. Each era has had a better 
patient (Fig. 41-17) and graft (Fig. 41-18) survival 
100 
\ 
rate than the one before it. It is thought that the 
advancements in immunosuppression were responsible 
for this improvement rather than nonspecific factors, 
such as the acquisition of more experience. Evidence 
other than raw survival supports this belief. 
In another analysis, aU FK 506-treated liver recipi-
ents were compared with recent historical control pa-
tients treated with cyclosporine. The controls were 
matched for underlying disease, age, and urgency 
status at the time of transplantation. The results in the 
first 40 consecutive liver recipients treated with FK 506 
vs. 35 cyclosporine-treated controls 3 months after 
transplantation are shown in Table 41-4. In addition 
to improved survival in the FK 506 recipients, other 
significant advantages were the reduced incidence of 
fatal infections and the reduced dependence on pred-
nisone, azathioprine, OKT3, and antihypertensive 
medication. 
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nGURE 41-18. Graft survival in pediatric liver 
transplantation recipients; FK 506 vs. cyclospor-
ine vs. azathioprine . 
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TABLE 41-4. Use of FK S06 in Pediatric Liver 
TraDsplantation: Comparison with Cyclosporine Historical 
Control Subjects at 90 Days 
FKS06 Cyclosporine 
Number analyzed 40 35 
Survival 36/40 26135 
Number of retransplantations 4/40 5/35 
Days of first hospitalization" 29.5 42.0, P = .005 
ICU days" 8.9 12.5 
Rejection/pt' 0.5 0.7 
Infection episodes/pt" 1.1 1.5 
Deaths due to infection 1 6, P = .06 
Patients receiving other drugs: 
Prednisone 10/36 26/26, p <0.001 
Antihypertensive agents 2126 11126, P < 0.001 
OKTI 5/40 12135, P = 0.04 
Azathioprine 0/36 16126, P < 0.001 
BUN values: 
Maximum' 46.3 47.6 
At discharge' 19 21 
Creatinine levels 
Maximum' 1.1 1.1 
At discharge' 0.38 0.47 
• Mean values. 
Effect of Recipient Size 
Low body weight, especially in pediatric liver recipi-
ents, has been viewed in the past as a poor prognostic 
factor because of technical problems in anastomosing 
tiny hilar vessels. However, routine microsurgical tech-
niques may have narrowed this gap. A possible trend 
toward the improved survival in infants under 10 kg 
may have occurred at our own center in that the 1-
year survival rate, which was 59% in 1985, improved 
to 77% in 1989 (Fig. 41-19). In addition to better 
survival. the number of recipients weighing less than 
10 kg has increased. Between 1981 and 1984, only 16% 
of our liver transplant recipients were under 10 kg. 
Since 1988, over 40% of recipients are this small (Fig. 
41-20). 
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Previous Operation 
Children with biliary atresia suffer higher than average 
perioperative morbidity and mortality rates, which may 
be attributed to difficulties caused by previous surgical 
procedures. At particular risk are children who have 
had multiple previous operations compared with those 
who have had a single Kasai's procedure (Fig. 41-21). 
Prognosis 
The better the patient's condition at the time of trans-
plantation, the better the prognosis. This can be dem-
onstrated graphically in cholestatic disease, in which 
jaundice is a reliable index of the patient's general 
condition (Fig. 41-22). This kind of information should 
influence the decision about when to proceed, a judg-
ment that should include the parents, primary physi-
cian, and transplant surgeons. If the disease progresses 
to a terminal illness, finding an organ in time may be 
impossible. Even with an organ available, the penalty 
of the decision to procrastinate could make transplan-
tation futile. 
AUXILIARY LIVER 
TRANSPLANTATION 
Auxiliary liver transplantation as an alternative to 
orthotopic liver transplantation (OLTx) has two theo-
retic advantages: (1) avoidance of the native hepatec-
tomy with its technical complications and (2) retention 
of the residual function of the diseased native liver, 
which may be substantial in some diseases, such as 
biliary atresia. It is self-evident that in some disorders 
(e.g., malignant tumors and hepatic infection or necro-
sis) removal of the native liver is an essential require-
ment. 
Auxiliary transplantation fell into disrepute, because 
of the overwhelming mortality rate following clinical 
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trials. In addition, it was discovered that these hetero-
topic allografts required portal revascularization with 
blood from the hormone- and nutrient-rich blood re-
turning from recipient viscera. The finding was thought 
to be due to competition for vital portal flow with the 
native liver. Finding a means of diverting portal flow 
through the graft presents its own set of difficulties. 
Interest in auxiliary transplantation was reawakened 
in 1988 by a report from Holland of several successful 
cases. However, further trials by the Dutch group and 
additional unpublished experience in other medical 
centers have not resulted in optimistic follow-up claims. 
AVAILABILITY OF ORGANS 
The acceptance of liver transplantation as a conven-
tional form of therapy was a phenomenon of the 1980s. 
Because its application will be or already has been 
100 
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FIGURE 41-20. Percentage of pediatric liver 
transplants in patients under 10 kg by year. 
limited by the availability of organs, several strategies 
to increase the supply have been examined. 
Living Donors 
The left lobe or left lateral segment is removed from 
a parent or other adult live donor. After back table 
vascular reconstruction of the removed fragment, the 
complete left lobe or lateral segment is transplanted to 
the recipient in the orthotopic location. This procedure 
requires a high level of skill for both the donor and 
recipient operations. Apart from the technical prob-
lems, this tactic has raised the sensitive issue of live 
donation and its associated physical risks. Some have 
argued that it is virtually impossible to obtain informed 
consent, especially in cases of emergency in which the 
procedure would be most useful. To date, there have 
been no deaths after partial hepatectomy in these 
donors. Recipient survival has been comparable to that 
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of cadaveric liver transplantation. Experience has been 
limited to a few centers. 
Donor Sharing 
With the so-called split liver technique, one recipient, 
usually an adult. is given the right lobe of a cadaver 
liver and another. usually a child, is given the left lobe 
or lateral segment. The division is carried out on the 
back table where vascular reconstructions are usually 
required. Although promising, this technique has 
yielded inferior results for both members of the recip-
ient pair. 
Animal Organs 
Liver heterotransplantation with chimpanzee donors 
was attempted three times, 18 or more years ago, with 
maximum survival of 9 days. The histopathologic find-
ings at autopsy were not distinguishable from those in 
allografts at comparable times. No further attempts 
have been made utilizing modern immunosuppression, 
and they are not likely, because of the endangered 
status of chimpanzees and increasingly recognized hu-
man-like qualities. Whether the plentiful baboon with 
its seemingly more distant anthropomorphic separation 
might be more socially and ethically acceptable is a 
matter that has been, and will be, hotly debated, as 
'xemplified by the outcry after earlier experience with 
,aboon-to-human kidney heterotransplantation and 
the Baby Fae heart heterotransplantation. 
Even granting the probity of baboon donor grafts, 
the current techniques of immunologic control proba-
bly are inadequate to permit the acceptance of such 
grafts. In all baboon organs transplanted so far, stig-
mata have been found of a delayed humoral rejection, 
which blocked the transplant blood supply after 7 to 
60 days. This humoral antibody barrier becomes more 
extreme roughly in proportion to the degree of species 
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disparity, so that with widely divergent species (xeno-
transplantation) rejection occurs within a few minutes. 
More than 25 years ago when dialysis was not 
available, Kuss of France, the pioneer transplant sur-
geon, attempted a pig-to-human renal transplantation. 
The kidney functioned well with azathioprine and 
prednisone immunosuppression but underwent hyper-
acute rejection. The dominant finding was the wide-
spread thrombosis of the microvasculature. concen-
trated in the venules. Kuss' willingness to share this 
experience almost 3 decades later was important, be-
cause the pig has been suggested as a possible organ 
source for humans. It would be difficult today to 
acquire the kind of vitally needed information about 
the vigor and nature of pig xenograft rejection in 
humans, which Kuss obtained under different circum-
stances at an earlier time. 
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